TrialPath
← Back to searchRecruiting

LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer

NCT06778512 · The First Affiliated Hospital of Guangzhou Medical University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics
About this study
This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.
Eligibility criteria
Inclusion Criteria: 1. Signing of the informed consent form; 2. Male or female, aged 18-75 years; 3. Patients with lung nodules confirmed by CT examination; 4. Good preoperative pulmonary function cooperation and complete reporting; 5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging; 6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month. Exclusion Criteria: 1. Poor preoperative pulmonary function cooperation or missing reports; 2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission; 3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month; 4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.); 5. Coexisting with other severe functional impairments; 6. Patients with obstructive lesions such as airway or esophageal stenosis; (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Study design
Enrollment target: 2500 participants
Age groups: adult, older_adult
Timeline
Starts: 2019-06-01
Estimated completion: 2026-12
Last updated: 2025-01-16
Interventions
Other: Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t
Primary outcomes
  • Area Under the Curve (3 years)
Sponsor
The First Affiliated Hospital of Guangzhou Medical University · other
Contacts & investigators
ContactJianxing He, Professor · contact · drjiaxing.he@gmail.com · 86-20-83337792
All locations (1)
the First Affiliated of Guangzhou Medical UniversityRecruiting
Guangzhou, Guangdong, China
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer · TrialPath